# Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

> **NCT03436485** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 204 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** ODM-208
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT03436485
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-03-19
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03436485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03436485, "Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03436485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*